TrialWatch: TherapeuticsMD REPLENISH Trial

Feb 9, 2019 | Positive Results, Women's Health

Lead investigator Regerio A. Lobo recently authored a summary in Healio on the REPLENISH trial sponsored by TherapeuticsMD. The FDA approved bioidentical estradiol and progesterone capsules (Bijuva) in October, following the results from the REPLENISH trial. This study demonstrated that a combination of 17beta-estradiol and progesterone appears to be safe and effective for reducing hot flash frequency and severity in menopausal women with a uterus. The study revealed that an oral dose of 100mg progesterone in a bioidentical hormone therapy combination that includes estradiol is sufficient to counteract potential estrogenic stimulation of the endometrium while improving moderate to severe vasomotor symptoms associated with menopause. See the link below to read up on more details from Dr. Lobo in regards to the REPLENISH trial.

Lead Research

Rogerio A. Lobo


Pin It on Pinterest